AngioDynamics slides after Q1 revenue miss [Seeking Alpha]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Seeking Alpha
The Latham, New York-based firm focused on vascular diseases reported $67.5M in net sales for the quarter compared to $67.9M in the consensus as its Med Device division underperformed. While ANGO's Med Tech division brought $28.0M in net sales with ~9% YoY growth, Med Device contracted, generating only $39.5M and implying a ~4% YoY drop. Gross margins at both businesses slumped, with the Med Tech business implying as much as a 160-bps drop in its gross margins for the quarter. However, AngioDynamics ( ANGO ) beat the consensus with its bottom line, as its adjusted net loss per share for the quarter fell ~31% YoY from the prior year period. As for guidance, the company reaffirmed its full-year outlook, indicating $282M-$288M in net sales and $0.38-$0.42 in adjusted net loss per share compared to $284M and $0.41 in the consensus. Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics launches long-term study of NanoKnife for prostate cancer [Yahoo! Finance]Yahoo! Finance
- ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE [Yahoo! Finance]Yahoo! Finance
- AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® SystemBusiness Wire
- AngioDynamics' NanoKnife System gains CPT codes for prostate and liver treatments [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and LiverBusiness Wire
ANGO
Earnings
- 10/3/24 - Miss
ANGO
Sec Filings
- 10/23/24 - Form SC
- 10/10/24 - Form 4
- 10/8/24 - Form 4
- ANGO's page on the SEC website